VerityRankVerityRank
Back to Rankings
Danaher Corporation
Manufacturer VerifiedUnited States

Danaher Corporation

Danaher

Danaher Corporation is a globally leading provider of scientific and technological products and services, headquartered in Washington, D.C., USA. The company focuses on three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Through a series of strategic acquisitions and integrations, it has built a diversified portfolio spanning high-end analytical instruments, clinical diagnostic systems, and industrial measurement devices. Reporting revenue of approximately US$32 billion in FY2025, Danaher stands as a paradigm of creating value through systematized operations. This is achieved by leveraging its renowned "Danaher Business System" (DBS)—a unique lean management and continuous improvement operating model that drives exceptional post-acquisition integration capabilities and operational efficiency—and its precise positioning in high-growth, high-margin niche markets.

Strengths: Danaher's core strength is its industry-famous "Danaher Business System" (DBS), a unique operating system centered on lean management and continuous improvement, which provides unparalleled efficiency gains and value-creation capabilities for both acquisition integration and organic operations.

Weaknesses: The company's main weaknesses are the high dependency of its growth strategy on a continuous stream of successful acquisitions, which carries inherent risks related to deal execution, integration failures, and overvaluation; and the intense technological competition and market pressure it faces in numerous segments from larger rivals like Thermo Fisher Scientific and many specialized competitors.
Read More ▼
United StatesEst. 196963,000$24.6B (2025)90+ Production BaseNYSE:DHRScore 89
Last Updated: August 2026·By VerityRank Research Team·Methodology

Business Nature

Danaher Corporation, through its Cytiva subsidiary, is the leading provider of bioprocessing equipment and automation systems for CGT manufacturing. The Sefia automated cell therapy production platform, developed in partnership with Kite Pharma, represents a breakthrough in closed-system CAR-T manufacturing. Cytiva equips virtually every GMP cell therapy facility globally with chromatography systems, bioreactors, and purification technologies.

Core Business Areas

- Bioprocess equipment Cytiva - Cell therapy automation platforms Sefia - Chromatography and purification systems - Cell culture media and bioreactors

Industry Rankings

Corporate Report

Core Business

Danaher Corporation, through its Cytiva subsidiary (formerly GE Healthcare Life Sciences), is the leading provider of bioprocessing equipment and automation systems for CGT manufacturing. The Sefia automated cell therapy production platform, developed in partnership with Kite Pharma, represents a breakthrough in closed-system CAR-T manufacturing automation. Cytiva's chromatography systems and cell culture technologies are used in virtually every CGT production facility worldwide.

Global Presence

Danaher operates across 60+ countries with approximately 63,000 employees. Cytiva's 16,000 specialized employees design and manufacture bioprocess equipment across North America, Europe, and Asia. The company's 2025 revenue of $24.6 billion provides substantial resources for continued CGT technology investment.

Key Strengths

Danaher/Cytiva's unique combination of precision manufacturing, automation expertise, and deep CGT industry partnerships enables it to provide the essential production infrastructure for the world's leading cell therapy facilities. The Sefia platform, developed with Kite, has demonstrated a 50% capacity increase in clinical settings. Cytiva's installed base in virtually every GMP cell therapy facility creates significant switching costs for customers.

VerityRank Score

Danaher (Cytiva) achieves a VerityRank Score of 89/100, reflecting its essential equipment provider position, breakthrough automation platform, and deep integration into the global CGT manufacturing infrastructure.

VerityRank Score

89/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Washington, D.C., USA

Founded

1969

Employees

63,000

Revenue

$24.6B (2025)

Factories

90+ Production Base

Listing

NYSE: DHR

Categories

Instruments & Meters ManufacturersMedical Consumables & Diagnostic Reagents CompaniesBiopharmaceuticalMedical Consumables & Diagnostic Reagents Manufacturers & SuppliersInstruments & Meters CompaniesGene & Cell Therapy Manufacturers & SuppliersInstruments & MetersIndustrial Automation Systems IndustryScientific Analytical Instruments Industry​Pressure Measurement Instruments Industry

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website NYSE:DHR , Danaher FY2025 Annual Results
Danaher Q4 FY2025 Press Release
Danaher 2025 Corporate Overview
Wikipedia: Danaher Corporation